ArticleAnnals of medicine2026
Evolution of alpha-Gal synthesis - a growing risk for alpha Gal syndrome.
Article in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlpha-Gal syndrome (AGS) is a growing burden worldwide associated with arthropods and allergies with pathologies such as urticaria, digestive and anaphylactic reactions. These reactions commonly appear 2-6 h after consumption of mammalian meat and derived pharmaceuticals mediated by immunoglobulin E against the oligosaccharide alpha-Gal epitope.
objectiveDespite the increasing incidence of AGS, it is underdiagnosed and requires information and initiatives to reduce disease risks and incidence while improving prevention and treatment. CONTENT: Our hypothesis is that Galactosyltransferase associated with alpha-Gal synthesis appeared and evolved in bacteria during the Mesoproterozoic Era ca. 1000 million years ago (Mya). Then, in Mollusca during the Cambrian and in Arthropoda and Mammalia during the Triassic period associated with improved fitness in organisms repopulating the Earth after Permian-Triassic Great Dying extinction event but affected Hominidae leading to catastrophic selection in the Oligocene.
conclusionsWith global rapidly changing climate and population dynamics, it should be considered that multiple arthropod species evolved to synthesize alpha-Gal as a guidance to develop preventive and control measures to reduce the risks of exposure to AGS. Accordingly, research should focus on the role of other organisms in addition to ticks in the evaluation and prevention of risks associated with the AGS with education for patients and medical staff to improve prevention and management of patients with AGS.Key messagesThe alpha-Gal synthesis evolved across multiple Arthropoda, Mollusca and MammaliaHominids developed to produce anti-alpha-Gal antibodies with protective capacityAlpha-Gal syndrome (AGS) in humans is associated with arthropods and allergic reactionsOther organisms are potential overlooked sources of alpha-gal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.